Aeolus Pharmaceuticals' Unattributed VC Round

Aeolus Pharmaceuticals raised a round of funding on July 07, 2003. Investors include Xmark Asset Management.

Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. AEOL 10150 is a…

Articles about Aeolus Pharmaceuticals' Unattributed VC Round: